CD8A and neoplasm: In the mouse model bearing B16 tumors, vaccination with Man-CTS-TCL NPs reduced the tumor mass and increased the number of CD8+ T cells in the spleen, indicating that Man-CTS-TCL NPs possessed great antitumor effects.